Medicine and Health

A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein

W. Pang, Y. Lu, et al.

The emerging SARS-CoV-2 variants threaten vaccine efficacy, prompting the need for a variant-proof solution. Researchers, including Wei Pang and Ying Lu, have developed HR121, a recombinant subunit vaccine targeting a conserved region of the S2 subunit of the spike protein. HR121 has shown promise in eliciting potent cross-neutralizing antibodies and providing protection against various SARS-CoV-2 strains, showcasing its potential as a game changer in the fight against COVID-19.